Pharmaceutical drug delivery market and systems
Pharmaceutical Technology
MARCH 22, 2024
Download our free, comprehensive list of the leading companies within the pharmaceutical drug delivery market.
Pharmaceutical Technology
MARCH 22, 2024
Download our free, comprehensive list of the leading companies within the pharmaceutical drug delivery market.
Bio Pharma Dive
AUGUST 8, 2023
The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 23, 2024
The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.
Fierce Pharma
APRIL 4, 2024
Amylyx Pharmaceuticals is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. Amylyx is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial.
World of DTC Marketing
DECEMBER 3, 2020
Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. The disconnect between consumers and prescription drug marketing has grown quite a bit. What about marketing to doctors? The other issue is a payment to physicians.
World of DTC Marketing
AUGUST 10, 2022
CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. But, in pharma marketing, the changes affect every product category. However, DTC marketing is different, much different. So what’s the opportunity for DTC marketers?
pharmaphorum
APRIL 4, 2024
Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.
Let's personalize your content